STOCK TITAN

T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
T2 Biosystems, Inc. (NASDAQ:TTOO) will report financial results for Q4 and full year 2023 and business updates on February 15, 2024. A conference call will be held at 4:30 p.m. ET. Investors can access the live webcast at www.t2biosystems.com or dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with passcode 106354.
Positive
  • None.
Negative
  • None.

LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the fourth quarter and full year 2023 and business updates after market close on Thursday, February 15, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International), passcode 106354, approximately ten to five minutes prior to the start time.

About T2 Biosystems:

T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care through the rapid detection of bacterial and fungal pathogens which allow faster targeted antimicrobial treatment. T2 Biosystems’ products are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology and include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2Biothreat™ Panel. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance® Panel, expanded T2Bacteria Panel to add Acinetobacter baumannii, the Candida auris test, and the T2Lyme™ Panel. For more information, please visit www.t2biosystems.com.

Investor Contact:
Philip Trip Taylor, Gilmartin Group
ir@T2Biosystems.com 
415-937-5406


FAQ

When will T2 Biosystems report financial results for Q4 and full year 2023?

T2 Biosystems will report financial results for Q4 and full year 2023 on February 15, 2024.

How can investors listen to the conference call?

Investors can access the live webcast at www.t2biosystems.com or dial 1-888-506-0062 (US/Canada) or 1-973-528-0011 (International) with passcode 106354.

What time will the conference call be held?

The conference call will begin at 4:30 p.m. Eastern Time.

T2 Biosystems, Inc

NASDAQ:TTOO

TTOO Rankings

TTOO Latest News

TTOO Stock Data

9.55M
8.59M
10.17%
73.51%
4.78%
Diagnostics & Research
Surgical & Medical Instruments & Apparatus
Link
United States of America
LEXINGTON